NCT06975644

Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)

A Prospective Clinical Study Evaluating Bemotuzumab Combined With Chemotherapy to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 55 (estimated)
• Sponsor: Zhejiang Provincial People's Hospital · Academic / Other
• Sex: Female
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Evaluating Bemotuzumab to improve the efficacy of neoadjuvant chemotherapy for Triple-Negative Breast Cancer (TNBC)

Detailed description

This study aims to prospectively evaluate the pathological complete response (pCR) rate in patients with early-stage triple-negative breast cancer (TNBC) receiving standard neoadjuvant chemotherapy combined with bemotuzumab.

Conditions

• Triple-Negative Breast Cancer (TNBC)
• Neoadjuvant Chemotherapy
• Chemotherapy Effects

Interventions

Type	Name	Description
DRUG	nab-paclitaxel, carboplatin, and bemotuzumab	nab-paclitaxel：260 mg/m2 Q3W；carboplatin：AUC 6；bemotuzumab：1200 mg Q3W
DRUG	epirubicin, cyclophosphamide, and bemotuzumab	epirubicin：90 mg/m2 Q3W；cyclophosphamide：600 mg/m2 Q3W；bemotuzumab：1200 mg Q3W

Timeline

• Start date: 2025-09-01
• Primary completion: 2026-09-01
• Completion: 2026-12-31
• First posted: 2025-05-16
• Last updated: 2025-05-22